Abstract
Sera from patients involved in a Peruvian outbreak of dengue virus serotype 1 infection cross-neutralized the American genotype of dengue virus serotype 2 up to 100-fold more efficiently than they did the virulent Asian genotype of dengue virus serotype 2, as determined by a plaque reduction neutralization test (PRNT) with CV-1 fibroblasts modified to express human Fcγ receptor CD32. The concordant preferential immune enhancement of the Asian genotype of dengue virus serotype 2 in human monocytes suggests that such a modification might strengthen the correlation between the PRNT titer and protection.
| Original language | English |
|---|---|
| Pages (from-to) | 285-287 |
| Number of pages | 3 |
| Journal | Clinical and Vaccine Immunology |
| Volume | 16 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 2009 |